Day: 16 8 月, 2025

SINGAPORE, Aug 16, 2025 - (ACN Newswire via SeaPRwire.com) - A 2022 survey from Vanson Bourne revealed that around 91%1 of respondents saw increased demand for automation from business teams. As AI technology evolves, that demand will only grow. AI automations can help organizations work smarter at every level. But how exactly do these workflows function? This article unpacks what AI workflow automation is and how it works behind the scenes.What is AI workflow automation?AI workflow automation is the use of artificial intelligence to automate complex, multi-step tasks that typically require human decision-making. While rule-based automation may rely on rigid instructions, AI automation adapts to data patterns. It learns over time and can flexibly handle unstructured input like emails, documents, or customer requests.AI workflow tools can understand, decide, and act based on context. These tools can help streamline processes and reduce manual effort while improving speed and accuracy.How do AI workflows function?AI workflows function by connecting a series of intelligent tasks or steps to complete a goal from start to finish. The specific tasks can vary depending on the use case. Some workflows may be entirely automated, while some may require human input. Let's take a closer look at some core components that power AI workflows.Machine learning (ML)Machine learning models can make predictions, identify problems, or find patterns. Machine learning has many uses in a workflow including classifying documents or prioritizing tasks. ML acts as the "decision engine", helping automate steps that would otherwise require manual analysis or classification.Natural language processing (NLP)NLP allows AI systems to understand and interpret human language for seamless communication. It's a crucial component in workflows that involve text, speech, or communication. For example, NLP can automatically extract key data from emails or summarize meeting notes. This enables organizations to automate content-heavy tasks without sacrificing understanding or context.Automation triggersAI workflows are usually event-driven. A trigger might be a form submission, a task status update, or an incoming message. Once initiated, the AI workflow executes a sequence of tasks based on logic, conditions, and model predictions. These triggers help organizations respond faster, reduce delays, and eliminate manual intervention.Predictive algorithmsPredictive AI models help forecast future outcomes based on past behavior. These algorithms can be used to detect workflow bottlenecks or even predict them based on past occurrences. Effective predictive models require good data and smart integration. When done right, they can help businesses make smarter, data-informed decisions with minimal human input.Benefits of AI workflowsHere are some of the advantages that AI workflows offer.Increased efficiency: Automations can take on repetitive and time-consuming tasks. This frees up teams to focus on more strategic work.Scalability: AI workflows can process large volumes of data or requests without extra headcount. They make it easier to scale services or operations.Improved accuracy: Trained models and rule-based logic may help reduce the risk of human error.Faster decision-making: AI workflows can analyze data and trigger decisions in real time. This may enable businesses to respond to problems or opportunities faster.From streamlining internal operations to powering real-time customer experiences, AI workflow automation is helping businesses scale their operations at a reduced cost. AI workflows offer a powerful path toward enhanced efficiency.[1] Vanson Bourne - Case studies Salesforce Business Demand for Automation. June 2022. https://www.vansonbourne.com/case-studies/business-demand-for-automation/CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: iQuanti Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC).Building on prior approvals in Singapore, Hong Kong SAR, and Macao SAR, as well as NDA acceptance in South Korea, this marks significant progress in the commercialization of VELSIPITY(R) across Asia. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R).As a next-generation selective S1P receptor modulator, once-daily oral etrasimod demonstrates robust efficacy across multiple endpoints, including clinical remission, mucosal healing, endoscopic normalization and histological remission. Its clinical value has been robustly demonstrated in multiple global Phase III studies, including ELEVATE UC 52, ELEVATE UC 12 and ENLIGHT (ES101002) studies.“The NDA acceptance for VELSIPITY(R) in Taiwan, China marks another key progress in our commercialization pathway across Asia. As the number of UC patients in Asia continues to rise, there remains a significant unmet medical need. In China alone, there were approximately 800,000 patients with UC in 2024, and the number is estimated to reach 1 million by 2030. UC patients face the dual challenges of long-term treatment and maintaining quality of life." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “This NDA acceptance underscores the clinical value of VELSIPITY(R). We remain committed to accelerating access to this innovative therapy in Mainland China and other Asian markets, supporting long-term disease management while enhancing patients’ quality of life.”The clinical part submitted to TFDA is mainly based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) and the ENLIGHT study (ES101002). The ELEVATE UC Phase 3 registrational program evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.The ENLIGHT study (ES101002) conducted by Everest, is a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including China Mainland, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately to severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The results demonstrate that treatment with etrasimod 2 mg resulted in a clinically meaningful and statistically significant improvement in the primary and all secondary endpoints. These findings provide strong evidence supporting the use of etrasimod in adult Asian patients with moderately to severely active ulcerative colitis.As Everest’s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its interim results for the six months ended 30 June 2025.Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG Guoxiong (center), Executive Director and Chief Executive Officer Ms. OU Haijing (left), and Chief Financial Officer Mr. KWAN Chi Fai (right)2025 Interim Results Highlights:- Overall operation was stable, with total revenue of RMB966 million (corresponding period of 2024: RMB1,034 million).- As at 30 June 2025, the overall occupancy rate of the properties was 82.2% (corresponding period of 2024: 84.0%).- The average financing cost was 3.33%, representing a decrease of 83 basis points from the beginning of the year. Excluding exchange loss, financing expenses decreased by 13.5% year-on-year.- Interim distribution of approximately RMB0.0333 per unit, equivalent to approximately HK$0.0366. This represents an annualized distribution yield of 8.42%.Guangzhou International Finance Center (GZIFC):- Operating revenue of the GZIFC complex was RMB486 million, accounting for 50.3% of the REIT’s total revenue.- Its office building introduced a Fortune Global 500 company, the occupancy rate was 82.6%, and the renewal rate was 70%.- GZIFC Shopping Mall had a high occupancy rate of 96.4% during the period.- Four Seasons Hotel Guangzhou achieved a 1.1-percentage-point year-on-year increase in average occupancy rate with record room revenue for the period, while Ascott Serviced Apartments GZIFC recorded a 1.8-percentage-point rise in average occupancy and similarly reached historic highs in revenue.Yuexiu Financial Tower:- Yuexiu Financial Tower recorded operating revenue of approximately RMB165 million, representing 17.1% of the REIT’s total revenue. The occupancy rate was 82.1%.- The tenant structure continued to improve, with new introduction of quality tenants such as a Fortune Global 500 company and a futures company with a market value exceeding RMB10 billion.Proactive Management of Financing Risk and Effective Stabilization of Financing Cost- With regard to the short-term loan of RMB530 million and the 5-year syndicated loan of HK$2.1 billion, both due in the first half of 2025, and other loans which are due within the year, the Manager in the first half of 2025 renewed the short-term loan of RMB530 million, obtained offshore loan of RMB1.7 billion and issued dim sum bonds of RMB1 billion for the refinancing and early repayment of the maturing loans so as to ensure effective monitor on the liquidity risk.- The Manager introduced a total of RMB3.23 billion in loans in the first half of 2025 to refinance offshore HKD floating rate loans, taking advantage of the relatively low-cost of RMB financing to proactively adjust the financing structure, thereby minimizing the impact of the interest rate market. At the end of the first half of 2025, the financing interest rate exposure of Yuexiu REIT was approximately 14%, narrowing by 12 percentage points from 26% at the beginning of the year; the average financing cost was 3.33%, representing a decrease of 83 basis points from 4.16% at the beginning of the year; the average interest payment rate for the first half of the year was 3.92%, representing a year-on-year decrease of 64 basis points. Excluding the exchange loss, the finance expenses amounted to approximately RMB402 million, representing a year-on-year decrease of 13.5%.- As at the end of June 2025, Yuexiu REIT had RMB financing of approximately RMB14,795 million, accounting for 72% of total financing (corresponding period of 2024: RMB financing of approximately RMB8,404 million, accounting for 41% of total financing).Mr. JIANG Guoxiong, Chairman and Non-Executive Director of Yuexiu REIT, said, "In the first half of 2025, against the backdrop of global trade volatility and slowing economic growth, China's GDP achieved steady growth of 5.3%, yet corporate expansion remained cautious and slow; retail consumption was weak, and average daily rate of hotel and apartment was under pressure. In order to effectively deal with the headwinds in the industry, we took strategic actions to secure market share by renewing leases in advance, investing in asset appreciation projects to enhance product competitiveness, and effectively stabilizing the fundamentals of operations, which effectively supported the revenue of Yuexiu REIT for the Interim Period. Meanwhile, lower financing cost is beneficial to the distributions.”Guangzhou International Finance Center (GZIFC)GZIFC achieved positive growth in both customer flow and conversion rates through product enhancement and operational optimisation, with a newly contracted area of 13,133 sq.m.. The newly launched 4,235 sq.m. of furnished units recorded an absorption cycle of only about 19 days, with an absorption rate close to 90%. Quality tenants introduced include a Fortune Global 500 company, a leading global shipping company, and a renowned Internet-based culture, sports and entertainment company, taking up more than 2,200 sq.m. in aggregate. In addition, the project recorded a renewed leasing area of 9,099 sq.m. and a renewal rate of 70%, retaining quality tenants including two Fortune Global 500 companies and a foreign consulate. GZIFC was selected as one of the Top 30 companies in the “Performance Index - 2025 Commercial Property Operation Performance” by Guandian.GZIFC Shopping Mall actively created digitalized consumption scenarios, advanced the pilot implementation of the local lifestyle platform “YueXiu Club”, which now covers 12 merchants, while attracting customers through multiple channels such as Dianping and UnionPay QuickPass platforms. Newly contracted area and renewed leasing area totaled 5,734 sq.m., with a renewal rate of 97% and the occupancy rate of 96.4%. During the period, it was announced that China Duty Free Group (CDFG) will set up a store in GZIFC Shopping Mall, which will be the first and currently the only downtown duty-free store in Guangzhou and is expected to open in the third quarter.Room revenue of Four Seasons Hotel Guangzhou and revunue of Ascott Serviced Apartments GZIFC reached a record high for the period, respectively. During the period, the average occupancy rate of Four Seasons Hotel Guangzhou reached 80.1%, representing a year-on-year increase of 1.1 percentage points. The average room rate was RMB2,201, similar to the same period last year. The revenue per available room (RevPAR) was RMB1,762, representing a year-on-year increase of 0.7%. The RevPAR competitive index was 111.7, maintaining a leading market position among luxury hotel competitors. The average occupancy rate of Ascott Serviced Apartments GZIFC reached 92.3%, representing a year-on-year increase of 1.8 percentage point and 9.7 percentage points higher than that of serviced apartment competitors. The average room rate was RMB1,128, similar to the same period last year. The RevPAR was RMB1,041, representing a year-on-year growth of 1.5%. The RevPAR competitive index reached 120.0.Yuexiu Financial TowerDuring the period, Yuexiu Financial Tower recorded a newly contracted area of 7,448 sq.m., including a total of 1,500 sq.m. further took up by seven existing tenants looking for expanded area. 7,089 sq.m. of furnished units were launched, with with an absorption cycle of approximately 38 days and an absorption rate of more than 65%. Quality tenants newly introduced include a Fortune Global 500 company and a futures company with a market value of over RMB10 billion. As certain tenants relocated to their own properties, the project recorded a renewed leasing area of 10,303 sq.m. and a renewal rate of 42%, retaining quality tenants with large leasing areas, including Deloitte, one of the Big Four international accounting firms, and a leading integrated asset management company in China.White Horse BuildingDuring the period, White Horse Building introduced supply chain resources from the Pearl River Delta and recorded a newly contracted area of 3,273 sq.m., with full occupancy on the 1st floor. In the first half of 2025, it welcomed a total of 165 procurement delegations, along with nearly 5,000 purchaser visits, including 23 foreign delegations from France, Vietnam and other countries, and facilitated procurement deals worth RMB140 million. By taking advantage of exhibitions such as the Greater Bay Area International Women’s Wear Expo and the Canton Fair, White Horse Building facilitated tenant transactions. It also successfully launched the cross-border e-commerce platform “White Horse Global E-Channel” and set up a series of courses titled “White Horse Business School Marketing Empowerment Camp” to activate new momentum for tenants’ digital operations.Fortune PlazaDuring the period, the project recorded a newly contracted area of 2,354 sq.m., and introduced quality tenants including several healthcare and elderly care subsidiaries of a Fortune Global 500 integrated financial group. The project recorded a renewed leasing area of 2,924 sq.m. and a renewal rate of 76%, retaining quality tenants including a Fortune Global 500 company, and flexibly adjusted units to match their demand for cost efficiency.City Development PlazaDuring the period, the project recorded a newly contracted area of 7,585 sq.m. and introduced a beauty technology company to enhance the ambience of healthcare business in the building. Retention plans were formulated in light of tenants’ pursuit of cost efficiency, aimed at optimizing product standards to meet tenant needs. The project recorded a renewed leasing area of 2,090 sq.m. and a renewal rate of 68%, retaining tenants including the Guangzhou office of a globally-renowned Contract Research Organisation (CRO).Victory PlazaDuring the period, its anchor tenant, Uniqlo, continued to play a flagship role by launching its C-series products, and hosted the first “A Better Life” campaign of Uniqlo in China, along with gigantic Pokémon installations and A Better Life Music Event, from 28 March to 6 April. Customer flow reached a quarterly peak during the events, driving a 7% year-on-year sales growth in April, and contributing to a 0.3% year-on-year sales growth during the Interim Period. By collaborating with tenants engaged in catering services to capitalize on increased sales with the surge in customer flow, the project drove a year-on-year increase of 0.6% in overall sales during the Interim Period.Shanghai Yue Xiu TowerDuring the period, the project recorded a renewed leasing area of 3,798 sq.m., with a renewal rate of 39%, while securing a newly contracted area of 3,933 sq.m., efficiently making up for the units surrendering ahead of lease expiry. By replacing the energy-saving light tubes in the carpark spaces to enhance brightness, the project enhanced both energy efficiency and service standards, thereby improving tenant satisfaction. As at the end of the Interim Period, the occupancy rate of Shanghai Yue Xiu Tower was 87.2%, representing a year-on-year increase of 2.6 percentage points.Wuhan PropertiesDuring the period, Wuhan Yuexiu Fortune Centre recorded a newly contracted area of 12,395 sq.m., and introduced quality tenants including a member of a leading global automobile group and a diversified professional services company. In addition, it recorded a renewed leasing area of 10,884 sq.m. and a renewal rate of 81%, retaining quality tenants with large leasing areas, including a Fortune Global 500 state-owned enterprise. The business solicitation team optimized the customers’ property visiting experience through partial micro-renovation of units, soft furnishing upgrades and creation of AI model rooms to increase the conversion rate of customers.Starry Victoria Shopping Centre recorded a newly contracted area and renewed leasing area totalling 3,894 sq.m. with a renewal rate of 82% during the period. The project successfully introduced several popular food and beverage brands, including the internet-famous brand “Domino’s” on the 1st floor of Hall A, to attract more family customer groups. The project tapped into nighttime consumption by leveraging the unique appeal of “Joy Garden” on the 4th floor, continuously developing initiatives like “Riverside Starry Night” and “Midnight Diner” to stimulate new sales growth drivers.Hangzhou VictoryHangzhou Victory recorded a newly contracted area of 1,974 sq.m. and introduced a tenant to take up an entire floor during the period. In addition, it recorded a renewed leasing area of 6,083 sq.m. and a renewal rate of 64%, retaining quality tenants including a Fortune Global 500 construction engineering company and the Zhejiang branch of a state-owned enterprise in Shanxi Province.ProspectsThe market generally hopes for further interest rate cuts by the US Federal Reserve in the second half of 2025, though the path and extent remain uncertain. On the other hand, 2025 marks the concluding year of China’s “14th Five-Year Plan”, with policies prioritizing stability, including moderately accommodative monetary policies and “trade-in” consumption subsidy policies aimed at expanding domestic demand to stimulate market vitality. Consequently, the Manager expects the RMB interest rate to remain at a relatively low level. With the accelerated development of new quality productive forces and the advancement of supply-side reforms in China, the Manager expects that new industrial momentum will continue to emerge and business environment will improve. The highly anticipated 15th National Games is scheduled to open in Guangzhou in the second half of 2025, which is expected to boost consumption in shopping malls and demand for hotels and apartments.In the second half of 2025, the Manager will keep abreast of economic development trends and dynamically implement proactive, prudent and flexible leasing strategies, keenly seize potential opportunities, and continuously enhance the market competitiveness of asset portfolio. The Manager will continue to review and make reasonable adjustments to its financing structure depending on expectations of market developments, and introduce low-cost RMB financing through various RMB financing channels to seek more favorable financing costs to offset interest rate risks. Additionally, the Manager will carry out relevant asset appreciation projects as planned, with reasonable planning and phased renovation of the guest rooms at Four Seasons Hotel Guangzhou. By focusing on product enhancement, equipment renewal and safety guarantee, the Manager aims to achieve value preservation and appreciation of the properties and ensure the sound operation of the projects.About Yuexiu Real Estate Investment TrustYuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. The current property portfolio comprises ten high quality properties, namely Guangzhou International Finance Center, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Yuexiu Financial Tower in Guangzhou, Yuexiu Tower in Shanghai, Wuhan Properties in Wuhan (including Wuhan Yuexiu Fortune Centre and Starry Victoria Shopping Centre), Victory Business Centre in Hangzhou and Yuexiu Building in Hong Kong, with a total area of ownership of approximately 1.184 million sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc.For media enquiries:Strategic Financial Relations LimitedVicky LeeTel: +852 2864 4834Email:sprg_yx@sprg.com.hk Phoebe LeungTel: +852 2114 4172 Maggie ZhangTel: +852 2864 4903 Websitehttp://www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the five-day (14-18 August) Food Expo, Beauty & Wellness Expo and Home Delights Expo open to the public from today at the Hong Kong Convention and Exhibition Centre. The Food Expo PRO, held concurrently from 14 to 16 August, is open to trade buyers for the first two days and to the public and trade buyers on the final day. For the first time, the Hong Kong International Tea Fair will be open to both industry professionals and the public throughout its three-day duration (14-16 August). The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM), organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also take place today and tomorrow (14-15 August).Due to Black Rainstorm Warning Signal, the opening of the fairs was delayed and the first session of the International Conference of the Modernization of Chinese Medicine was livestreamed.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will extend the opening hours to 11pm on 15-17 August. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August).Margaret Fong, Executive Director of the HKTDC, stated: "The 35th Food Expo celebrates an important milestone this year. The five-in-one mega event plays host to some 1,890 exhibitors from 36 countries and regions, serving as a one-stop destination and a vibrant marketplace for both trade professionals and consumers, where gourmet foods, fine teas, home essentials and beauty products can be found. Meanwhile, Food Expo PRO is dedicated to boosting Hong Kong’s status as a premier business hub for the food industry, not just in Mainland China, but across Asia and the globe. It empowers F&B professionals to explore new opportunities, forge valuable connections, and drive innovation.”Several exhibitors expressed that their special offers will remain unchanged. Among them, Phelix Pun from Ng Fung Hong Limited shared that staff arrived as usual this morning to prepare for the exhibition. They hope that, once the exhibition opens, it will continue to boost their business, with the planned special offers and interactive games proceeding as scheduled. They believe that citizens will continue to turn out enthusiastically to visit and shop.Five themed days create a quality living space1. Shall We Tea' (14 August)Today’s focus is on the variety of Chinese and Western tea beverages. This year, the Hong Kong International Tea Fair opens to the public for all three days for the first time, featuring pavilions from countries and regions such as Fujian, Hubei, Zhejiang, Kenya, and Sri Lanka to promote tea culture. Visitors can sample premium traditional teas like Bai Hao Yin Zhen (Silver Needle tea) (Booth: 5F-F01), one of the finest Chinese white teas, alongside wellness capsule tea (Booth: 5F-F05), and innovative new-style tea beverages from various regions (Booth: 5G-A21). The “Friends of Tea” Zone also offers tea-pairing snacks, tea-infused perfumes and more, offering a blend of traditional and modern tea culture experiences. Visitors can participate in various talks, including "The Legacy and Contemporary Dialogues of Chinese Tea Culture" and "The Beauty of Tea, Where Small Things Reveal Greatness”, as well as activities led by certified water sommeliers and tea masters exploring the diversity of water, decoding the secrets of tea flavours, and delving into the joy of tea appreciation.At the Food Expo, visitors can enjoy premium matcha and hojicha from Kyoto’s century-old Marukyu Koyamaen tea garden, blended with locally made fresh nut butter to create tea-flavoured gelato (Booth: 3B-E10). The Nin Jiom Tea Pairing Lucky Bag (Booth: 1C-A10) includes five functional teas with various health benefits. Additionally, Earl Grey tea infused with bergamot in drip-filter bags (Booth: 1D-A12) offers a refreshing citrus aroma.2. Flavours of Intangible Cultural Heritage (15 August)Despite its small size, Hong Kong boasts over 50 items on its intangible cultural heritage list related to food, showcasing its unique culinary culture. Exhibitors will present tea bags made with 100% Ceylon black tea, ready to brew for an effortless Hong Kong-style milk tea or Yuan Yang (Booth: 5F-F21). Additionally, there’s handmade shrimp paste from Hong Kong’s last remaining licensed salted fish and shrimp paste factory, capturing the authentic flavours of Hong Kong’s fishing village heritage (Booth: 1A-E02).The themed day features a series of activities centered on intangible cultural heritage. At the Home Delights Expo, master artisan Choi Wing-kei will share the story of preserving the traditional craft of floral plaque making, alongside demonstrations of Taiji and Wing Chun martial arts techniques, as well as introductions to the cultural significance of bamboo steamers and bamboo craftsmanship. The Food Expo will showcase demonstrations of making traditional Hakka Sau Fan. The Hong Kong International Tea Fair will host a seminar on "Chiu Chow Kung Fu Tea," exploring the distinctive tea culture of the Chaoshan region.3. Asian Delights (16 August)The day celebrates Asian cuisine and culture, featuring cooking demonstrations of Vietnamese dishes and molecular Thai cuisine, complemented by performances of the traditional Japanese shamisen, K-Pop dance, and a Thai yoga massage experience at the Beauty & Wellness Theatre, immerses visitors in the vibrant essence of Asia.At the Food Expo, the China National Agricultural Pavilion, organised by the Agricultural Trade Promotion Centre, the Ministry of Agriculture and Rural Affairs of Mainland China, will present a thousand agricultural and food products from 13 provinces, such as Korla fragrant pears, Xinjiang safflower seed oil, rainbow trout salmon, Guangdong lychee black tea, Lianzhou mustard greens, Hainan Wuzhishan large-leaf tea, Northeast black soil organic rice, and Yantai apples from the Qilu region.Visitors can explore a range of premium products at the Food Expo PRO. The 100% natural, hand-picked wild pine nut oil from Mongolia (Booth: 5C-G20) is a healthy choice for daily diets. A whisky from Soni Village in Nara Prefecture, renowned for its pristine spring water (Booth: 5B-B06), its smooth taste is perfect for a variety of uses, whether drinking neat, on the rocks, or mixed into a variety of cocktails. The spicy and crispy milk chocolate, made with Sichuan pepper oil, Espelette pepper, and almond paste filling (Booth: 3B-E04), would offer an unforgettable tasting experience.4. Body, Mind, and Soul (17 August)This year, the Beauty & Wellness Expo introduces the new "Scentsation” Zone, featuring over 20 brands showcasing a range of perfumes and aromatherapy products to nurture both mind and body. Making its debut at the expo, Lush (Booth: 3E-D08) presents its popular Deep Sleep Magnesium Massage Bar, designed to enhance sleep quality. In response to the growing opportunities in the silver economy, exhibitors are offering various products and services tailored for seniors. Mannings, participating in the Beauty & Wellness Expo for the first time, will feature a Smart Health Station, offering free health tests to help seniors select the best fit wellness products.The Food Expo, Beauty & Wellness Expo, and Home Delights Expo will host a series of seminars and activities, including hand massage workshops, discussions on the emerging trend of Hong Kong residents seeking cross-border medical care, towel exercise sessions, explorations of ergonomics and the latest treatments for various diseases, and diets to boost immunity. The performance stage will feature various sports demonstrations, such as taekwondo, street dance, and ballroom dancing.5. Taste HK (18 August)In recent years, organic farming has gained popularity, with growing demand for local produce. A cooking demonstration, co-organised by DRAGONS' DEN, the Vegetable Marketing Organization, and the Fish Marketing Organization at the Food Expo, will use local ingredients to create healthy and delicious home-cooked dishes. Additionally, the Home Delights Expo will feature notable products, including a glass-lined insulated handheld cup that won the 2024 Red Dot Product Design Award (Booth: 3F-D20), a water faucet awarded the 2023 Red Dot Design Award (Booth: 3F-B18), and a plug-and-play portable air conditioner that requires no exhaust duct (Booth: 3F-E25).At the Food Expo, visitors can savour a sparkling soda infused with lemon honey, salted plum, and ginger (Booth: 3B-A07), recreating classic Hong Kong flavors. A Kee Wah snack set paired with a cute panda backpack (Booth: 1E-C02) combines iconic treats. At the Food Expo PRO, traditional mooncakes developed by the Hong Kong Polytechnic University’s food team (Booth: 5C-C17) utilise exclusive AkkMore™ fungal fat-replacement technology, blending health with deliciousness.Exploring Halal Products, Coffee, and Food Science OpportunitiesThe 3rd Food Expo PRO and the 35th Food Expo have introduced a Halal food and beverage label since last year to assist exhibitors in expanding into the halal product market. This year, the two expos feature over 120 food suppliers showcasing halal products from around the world, a 20% increase compared to last year. The expo also strengthens collaborations with countries with thriving halal food markets. Group pavilions at the Food Expo PRO include ASEAN countries such as the Philippines, Thailand and Vietnam, enriching the variety of halal exhibits.The Food Expo PRO introduces a new "Coffee Zone" this year, showcasing coffee products, accessories, and machines from various origins. Yunnan Province, China’s leading coffee bean producer, is represented by several Pu’er City companies exhibiting Kunlu Mountain and Jinpaoshan roasted beans and other products. Another highlight, the "Food Science and Technology Zone”, presents alternative and future foods of interest to industry professionals. Today’s Food Tech Symposium explores the development of additive-free foods and clean labeling in Hong Kong. Exhibitors are also targeting the silver economy, showcasing innovative products such as soft-textured mooncakes and cognitive health supplements developed by local exhibitors.21 Prominent Speakers Discuss the Latest Developments in Chinese Medicine (14-15 August)The Modernized Chinese Medicine International Association, together with the HKTDC and ten scientific research institutions, provides industry professionals with the latest insights into Chinese medicine. Themed “The Latest Research Progress in the Prevention and Treatment of Tumors, Inflammation, and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine”, the conference secures 21 prominent speakers, including experts from Hong Kong, Mainland China, and overseas, sharing innovative achievements and trends in the globalisation of Chinese medicine. Conducted in a hybrid format, the conference offers broader opportunities for interaction with speakers. Hong Kong-registered Chinese medicine practitioners can also earn Continuing Medical Education credits by attending the conference.Food Expo Celebrates 35th Edition with Exclusive OffersTo celebrate the 35th Food Expo, free admission tickets are available each day before noon, with 350 each at Halls 3FG and 5FG entrances and redeemable with the designated advertisement. Over 100 promotions are priced at HK$35 or discounted by 65% to tie in with the 35th Food Expo. The “Food Expo 35th Edition – Treasure Hunt” game engages visitors in Hall 3, where they can hunt for ‘treasure’, scan QR codes, answer questions correctly, and redeem gifts. Together with daily lucky draws, prizes are worth over HK$1 million, including kitchenware, furniture, beauty products, gourmet foods, health items; a lucky draw entry is granted for a single transaction of HK$300 or more. The “Smart Bidding” session allows visitors to bid on favourite items starting at 10% of their original price. Visit the “August Happy Buy” promotional website for flash sales and exclusive discounts.Snoopy is celebrating its 75th anniversary this year. The organiser invites visitors to participate in the “Snoopy Hide & Seek” activity at the Home Delights Expo, where they can snap photos with Snoopy and friends for a chance to win special prizes, joining in the festive celebration.Physical ticket sales are unavailable at the venue. E-tickets can be purchased in advance through AlipayHK, Alipay, 01 Space, 7-Eleven, Circle K, Octopus app, or The Club app, or at venue entrances using AlipayHK, Alipay, or Octopus. Discounted “Morning Admission” and “Evening Admission” are offered on select dates.Photo download: http://bit.ly/3Hzud7QThe five exhibitions, including the 35th Food Expo, the 9th Beauty & Wellness Expo, the 11th Home Delights Expo, the 3rd Food Expo PRO, the 16th Hong Kong International Tea Fair, and the International Conference of the Modernization of Chinese Medicine and Health Products, officially opened today.The Food Expo PRO introduces a new "Coffee Zone” this year, showcasing coffee products, accessories, and machines from various originsThe 3rd Food Expo PRO and the 35th Food Expo feature over 120 exhibitors showcasing a variety of halal foods, facilitating procurement for buyersThe Hong Kong International Tea Fair will be open to both industry professionals and the public for the first time, with several regional pavilions, showcasing unique tea cultures and premium tea products from various regions to the public and trade buyersThe Food Expo’s Gourmet Zone features seven themed areas, offering everything from exquisite main courses and craft beverages to delicious dessertsA new “Scentsation” Zone debuts at this year’s Beauty & Wellness Expo and features over 20 perfume and aromatherapy brands, using fragrances to balance the body and mindHome Delights Expo showcases a variety of home tech products, such as Towngas’ steam washing machine with smart stain treatmentOpening dates and times of the exhibitions:DateHKTDC Food Expo PROOpen to trade buyers only: 14-15 August (Thursday to Friday)Open to trade buyers and public: 16 August (Saturday)Hong Kong International Tea FairOpen to trade buyers and public: 14-16 August (Thursday to Saturday)HKTDC Food Expo, HKTDC Beauty & Wellness Expo, HKTDC Home Delights Expo14-18 August (Thursday to Monday)International Conference of the Modernization of Chinese Medicine and Health Products14-15 August (Thursday to Friday)TimeHKTDC Food Expo PRO, Hong Kong International Tea Fair14-15 August: 10:00 am to 6:00 pm16 August: 10:00 am to 5:00 pmHKTDC Food Expo, HKTDC Beauty & Wellness Expo, HKTDC Home Delights Expo14-17 August: 10:00 am to 10:00 pm18 August: 10:00 am to 6:00 pmVenueHong Kong Convention and Exhibition Centre, Wan ChaiAdmission- Food Expo Public Hall, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair 2025 single ticket: HK$30 per person (ticketholders can pay a top-up fee of HK$10 for admission to the Gourmet Zone on the same day)- Food Expo Public Hall and Gourmet Zone, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair 2025 combo tickets: HK$40 per person**HK$36 per person during the pre-sale period from 31 July to 13 August (tickets are available for pre-sale and walk-in at all 7-Eleven and Circle K convenience stores for HK$36 per person.)Remarks: Holders of 16 August single ticket & combo ticket can visit the Food Expo PRO- Morning admission tickets: Entry before noon on 14, 15 and 18 August, Thursday, Friday and Monday, to the Food Expo Public Hall, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair on the same day: HK$10 (pay directly by AlipayHK, Alipay or Octopus card for admission at the hall entrances only)- Night admission tickets: Entry after 6:00 pm on 14 to 17 August, Thursday to Sunday, to the Food Expo Public Hall, Home Delights Expo, Beauty and Wellness Expo on the same day: HK$10 (pay directly by AlipayHK, Alipay or Octopus card for admission at the hall entrances only)- Concessionary price for persons with disabilities: HK$10 (top-up fee for the Gourmet Zone on the same day is HK$10) Note: Persons with disabilities need to present a “Registration Card for Persons with Disabilities”, issued by the Labour and Welfare Bureau (pay directly by AlipayHK, Alipay or Octopus card for admission at the hall entrances only)- Tourist tickets: HK$20 (HK$30 including admission to the Gourmet Zone)Note: Tourists need to present valid travel documents at the fairground to purchase tickets.Free admission is available for children aged three and under and senior citizens aged 65 or above (presenting valid age proof).TicketsE-tickets are available for sale at AlipayHK and Alipay, the 01 Space e-ticketing platform, all 7-11, Circle K convenience stores, Octopus app and The Club app.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comAugust Happy Buy websiteecoupon.hktdc.com/food/Media EnquiriesOgilvy Public RelationsRex CheukTel : (852) 5618 9908Email : rex.cheuk@ogilvy.comLeanne PokTel : (852) 9379 9694 Email : leanne.pok@ogilvy.comDaisy LeungTel : (852) 9275 7704Email : daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs DepartmentStanley SoTel : (852) 2584 4049Email : stanley.hp.so@hktdc.orgSerena CheungTel : (852) 2584 4272Email : serena.hm.cheung@hktdc.orgClayton LauwTel : (852) 2584 4472Email : clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the “Updated Guidelines”). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence.This milestone underscores the high level of recognition from an internationally respected clinical guideline for the therapeutic value of etrasimod and highlights its potential to address the significant unmet medical needs of UC patients, offering a new treatment option worldwide.The updated guidelines were developed by the American College of Gastroenterology (ACG) including the latest evidence from the past five years. They provide a comprehensive summary of new approaches and advances in the treatment and prevention of complications in UC, with the goal of offering clinicians standardized and evidence-based recommendations to better manage patients with varying degrees of disease severity.The updated guidelines note that, etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active UC. The S1P 1 receptor modulation regulates the trafficking of specific lymphocyte subsets out of the lymph nodes, leaving fewer peripheral immune cells available to traffic to sites of inflammation.The updated guidelines also reference the Phase III ELEVATE UC clinical study for etrasimod (ELEVATE UC 52 and ELEVATE UC 12). Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod. Etrasimod has been included in the AGA Living Clinical Practice Guideline on the pharmacological management of moderate-to-severe UC as one of the higher-efficacy medications suggested for first-line use in advanced therapy-naïve patients.Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial said “The updated guidelines further emphasize that achieving endoscopic mucosal healing to enable sustained, steroid-free remission is a core treatment goal for patients. This is not only critical for the long-term and safe management of the disease but is also closely tied to improving patients’ quality of life. The strong recommendation of etrasimod for both induction and maintenance therapy in this population reflects the high level of recognition from an internationally authoritative medical authority.”“The inclusion of etrasimod in the 2025 American College of Gastroenterology (ACG) Clinical Guideline for Adult Ulcerative Colitis, with a strong recommendation, is a clear recognition of its clinical efficacy and favorable safety profile. Mucosal healing is a recognized treatment goal in both domestic and international clinical guidelines for UC. Achieving mucosal healing at an early stage can significantly reduce the risk of disease relapse, hospitalization, colectomy, and the development of colorectal cancer.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “In Asia, the number of UC patients continues to rise, while treatment options remain limited, highlighting an urgent need for innovative therapies that balance efficacy, safety, and convenience. In China alone, the UC patient population was estimated at approximately 800,000 in 2024 and is projected to reach 1 million by 2030, placing an increasing burden on the healthcare system.”As a key innovative asset in Everest Medicines’ autoimmune disease portfolio, etrasimod’s inclusion in the clinical guidelines underscores its global therapeutic potential as a new treatment option for UC patients across Asia, including in China. We remain committed to accelerating the regulatory approval process for etrasimod in Mainland China, South Korea, and other Asian markets to enhance patient access and help more individuals achieve higher-quality, longer-lasting disease remission.”As a core product of Everest Medicines, etrasimod has been approved in Singapore, Macao SAR, and Hong Kong SAR, and its NDA has been accepted in South Korea. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R). As Everest’s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Copyright 2025 ACN Newswire via SeaPRwire.com.

Results Highlights:- Revenue reached US$83.6 million, a year-on-year increase of 5.9%.- Sales volume reached 919,000 units, of which 779,000 units were proprietary products, representing a year-on-year increase of 8.6%.- Profit attributable to owners of the company increased by 5.1% year-on-year to US$19.8 million.- Core operating profit amounted to US$15.1 million, an increase of 11.4% year-on-year.- The Board declared a special dividend of HK15 cents per share to mark the Group’s 25th anniversary.- The Group maintained a sound financial position with cash and bank balances of US$237.1 million as of June 30, 2025 to support potential acquisitions and the construction of new manufacturing facilities.- The Group’s high-quality products have gained widespread recognition worldwide, resulting in revenue growth of 14.0% in the APAC market, 17.0% in the EMEA market, and 20.0% in the US market.- The Group acquired a Taiwan-based distributor in the first half of the year. It also plans to establish direct sales teams in Belgium and the Netherlands in the second half of the year, further strengthening direct presence in APAC and EMEA markets.- Leveraging its global commercialization expertise and extensive distribution network, the Group established strategic partnerships with medical device peers, thereby diversifying its product portfolio and generating additional revenue through cross-selling opportunities.HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2025 (the “Period”), reporting growth in both revenue and net profit despite an uncertain macroeconomic landscape.The Group recorded revenue of US$83.6 million, up 5.9% over the previous year, driven by strong year-on-year growth in the US market, as well as continued contributions from emerging markets in APAC and EMEA. Core operating profit, being profit attributable to the owners of the Company excluding share-based compensation, net tax credit from deferred tax asset in relation to tax losses, and finance income/costs, amounted to US$15.1 million, up by 11.4% year-on-year. Profit attributable to the owners of the Company increased by 5.1% year-on-year to US$19.8 million. Basic earnings per share was US2.40 cents (first half of 2024: US2.28 cents).As of June 30, 2025, the Group maintained a strong financial position with cash and bank balances amounting to US$237.1 million. In light of the Group’s solid financial position and in celebration of the its 25th anniversary, the Board has resolved to declare a special dividend of HK15 cents per ordinary share, demonstrating the Group’s commitment to creating value for its Shareholders. Together with the final dividend of HK10 cents per share for the year ended December 31, 2024 paid on June 16, 2025, Shareholders will receive a total dividend of HK25 cents in 2025.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Over the past 25 years, we have continuously invested in innovation and global commercial capabilities, establishing OrbusNeich’s reputation and enabling us to navigate different economic cycles. Despite macroeconomic and geopolitical challenges in the first half of 2025, our global deployment proved resilient. Growth in the US market reflected strong demand for our high-quality products, while our extensive sales network successfully captured growth opportunities in the APAC and EMEA regions. We will continue to sharpen our competitive edge by enhancing brand value through our direct sales market presence, excellent sales support, commitment to innovation, and comprehensive PCI and PTA product portfolio, while advancing safer, more effective solutions for physicians and patients and delivering long-term returns to shareholders.”Global Sales Network and Partnerships Boost Revenue GrowthOrbusNeich has built a sales network spanning over 70 countries and regions, including direct teams in 13 locations and a global distributor network, which proven integral to capturing local opportunities and demand worldwide. APAC revenue rose by 14.0% year-on-year to US$27.3 million during the Period, fueled by growth in Indonesia and increasing adoption of Scoreflex TRIO in Singapore and Malaysia. EMEA revenue grew 17.0% to US$22.4 million, driven by strong proprietary balloon product sales in key direct markets (Germany, France, Spain) and distributor markets (the UK, Slovakia, Czech Republic). Despite tariff disruptions, US revenue increased by 20.0% to US$8.0 million, boosted by a notable surge in sales volume of standard and scoring coronary balloons and peripheral balloons, including the high-priced Scoreflex NC balloon. Revenue from the Japan and PRC markets was US$16.1 million and US$9.7 million, respectively.Leveraging its widely-recognized global commercialization expertise, the Group partnered with peers pursuing international expansion to enrich its product portfolio and drive additional revenue streams. Building on the successful collaboration with SonoScape Medical Corp. involving the distribution of intravascular ultrasound (“IVUS”) products in Hong Kong and Macau last year, the Group has entered into a sole and exclusive distribution agreement with this partner to distribute its IVUS products in Singapore and Malaysia. The collaboration now covers four additional direct European markets (France, Germany, Spain, Switzerland) and six other distributor markets across Europe.Performance-Led Innovation Fuels Market Distinction and Portfolio DiversityAs of June 30, 2025, OrbusNeich had obtained more than 250 granted patents and published patent applications in key jurisdictions worldwide, as well as over 55 approved products.During the Period, the Group made progress in terms of product registrations and clinical trials, including:- Sapphire 3’s US trial progressing smoothly, with patient enrollment set to finish in Q4 2025 to support FDA submission for the CTO indication, distinguishing it from other conventional semi-compliant balloons on the market;- Obtained CE Marks for JADE PLUS and Teleport Glide, PMDA approvals for Teleport Glide and Scoreflex QUAD, FDA approvals for the COREPASS Modular Microcatheter, and NMPA approval for the guiding catheter;- Submitted registration applications for Scoreflex TRIO, Sapphire ULTRA, Sapphire NC ULTRA, Sapphire NC 24, JADE PLUS, Teleport XT and Teleport Glide to the NMPA, and applications for the Vascuaid Aspiration Catheter and GCE Large Lumen to the PMDA.Regarding the Group’s robust product pipeline, the Sapphire PTX paclitaxel drug-coated balloon, in the coronary space, is set to begin clinical trials in Japan near the end of 2025. In the peripheral space, the JADE Score balloon is expected to be submitted for PMDA approval in 2026.The joint venture OrbusNeich P&F also made significant progress in the clinical trials of TricValve in the PRC, with the number of participating sites increased to accelerate patient enrollment. In addition, it has been actively promoting TricValve’s entry into hospitals in the Greater Bay Area (“GBA”) through the Hong Kong & Macau Registered Drugs and Medical Devices Access to GBA Program. The first commercial implantation of TricValve in the Mainland of China was completed in July 2025, marking the achievement of an important milestone.Multi-Region Production Bases Mitigate Evolving Geopolitical RisksAs of June 30, 2025, OrbusNeich’s aggregate annual production capacity was approximately 2.1 million balloons and stents, with production facilities in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany. Since acquiring eucatech AG in late 2023, the Group has allocated resources to restore its production capabilities, gradually ramping up output during the Period to supply products for both sales and clinical registries.The Group completed the main structure construction of its largest R&D and production facility in Hangzhou, the PRC, in August 2025, with renovation work expected to begin in the second half of the year. The facility is scheduled to commence operations in 2027, adding an annual production capacity of 2.4 million units.Mr. Chien concluded, “We remain optimistic about the second half of 2025 due to strong momentum in emerging markets, successful proprietary product launches, and strategic partnerships. APAC and EMEA will remain our key growth drivers, with plans to transition selected markets from distributor to direct sales models to enhance revenue and market presence. In Europe, we will establish direct sales teams in Belgium and the Netherlands to expand our footprint. The Japanese market will see renewed momentum through new product launches, while in the PRC market, we will capitalize on policy support to expand product coverage and accelerate commercialization. US shipments are expected to speed up amid easing tariff disputes. Backed by OrbusNeich’s diversified portfolio, strong financial position, and economies of scale, we are well positioned to build a resilient, competitive business that delivers sustainable value to stakeholders.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，旗下创新药艾曲莫德（VELSIPITY(R)，etrasimod）被纳入《2025 ACG 临床指南：成人溃疡性结肠炎》（下称"新版指南"），并获得强烈推荐用于中重度活动性溃疡性溃疡性结肠炎（UC）患者的诱导缓解及维持缓解治疗（中等质量证据）。新版指南同时建议，对于已通过鞘氨醇-1-磷酸（S1P）受体调节剂实现诱导缓解的患者，继续使用艾曲莫德以维持缓解（强烈推荐，中等质量证据）。这一重要进展不仅体现了国际权威医学指南对艾曲莫德临床价值的高度认可，也进一步彰显了其在满足UC患者未被满足的治疗需求方面的潜力，为全球UC患者提供新的治疗选择。此次新版指南由美国胃肠病学会（American College of Gastroenterology，ACG）制定，基于近五年最新循证医学证据，系统总结了UC治疗及并发症预防的新方法与新进展，为临床医生提供规范、科学的管理参考，以更好地应对不同程度的UC患者治疗需求。新版指南指出，艾曲莫德作为新一代高选择性S1P受体调节剂，通过将活化的淋巴细胞滞留于淋巴结中，减少其在肠道中的浸润，从而降低局部炎症反应，并伴随外周循环淋巴细胞计数下降。艾曲莫德ELEVATE UC III 期注册研究（ELEVATE UC 52和ELEVATE UC 12）这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，分别在第12周和第52周显著改善临床缓解率，并实现持久的内镜下深度黏膜愈合。值得注意的是，研究中100%的临床缓解均为无激素缓解，安全性良好，与既往研究结果一致。指南也特意强调了与其他现有治疗不同的是，艾曲莫德 ELEVATE UC III 期注册研究中纳入了溃疡性直肠炎，且证实了在此类人群中显著提升了临床缓解率（治疗12周时，43.2% vs 13.6%, p＜0.001）。此前，艾曲莫德还被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。艾曲莫德亚太临床试验牵头研究者、世界胃肠病学会司库、亚太消化病学会副主席、中华医学会第十届消化病学分会副主任委员、中国人民解放军第四军医大学附属西京医院吴开春教授表示："新版指南进一步明确，'实现内镜黏膜愈合以达成持续无激素缓解和避免住院手术'是中重度溃疡性结肠炎治疗的核心目标，这不仅关系到疾病的长期安全管理，也与改善患者生活质量息息相关。此次指南中，艾曲莫德被强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，标志着其临床价值获得了国际权威学术机构的高度认可，也为临床实践提供了全新的治疗选择。"云顶新耀首席执行官罗永庆表示："艾曲莫德此次获新版指南强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，充分体现了其卓越的临床疗效和良好安全性，进一步确立了其作为一线治疗新选择的重要地位。新版指南明确将实现内镜黏膜愈合作为治疗中重度活动性溃疡性结肠炎的核心目标，印证了黏膜愈合为国内外指南一致认定的重要终点，可显著降低疾病复发、住院、结直肠切除及结直肠癌风险。值得一提的是，指南特别强调了艾曲莫德在溃疡性直肠炎患者中同样可显著提升临床缓解率。在亚洲，溃疡性结肠炎患者人数持续上升，以中国为例，2024年中国的溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人，现有临床治疗选择有限，迫切需要兼顾疗效、安全性与便利性的创新方案。我们将加速艾曲莫德的商业化进程，助力更多患者长期维持安全有效的疾病缓解，并提升生活质量。"作为云顶新耀在自身免疫疾病领域布局的核心创新产品，艾曲莫德（维适平(R)）的新药上市申请已于2024年12月获中国国家药品监督管理局正式受理，预计今年年底或明年年初获批。艾曲莫德已在新加坡、中国澳门和中国香港获批，其新药上市许可申请也已在韩国和中国台湾地区获正式受理。艾曲莫德已被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（2024年），在大湾区先行使用，成为云顶新耀第三款商业化新药。云顶新耀已于2025年3月启动艾曲莫德在嘉善工厂的本地化生产建设项目，支持其在大中华区及其他亚洲市场的供应及商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

业绩亮点：- 收入达83.6百万美元，同比增长5.9%。- 销量达919,000件，其中779,000件为自有产品，同比增长8.6%。- 公司拥有人应占利润同比上升5.1%至19.8百万美元。- 核心经营利润达15.1百万美元，同比增长11.4%。- 为庆祝集团成立25周年，董事会宣派特别股息每股15港仙。- 财务状况稳健，截至2025年6月30日，现金及银行结余达237.1百万美元，支持潜在收购及新生产设施建设。- 优质产品获全球广泛认可，带动亚太地区市场收入按年增长14.0%，欧洲、中东及非洲市场增长17.0%，及美国市场增长20.0%。- 于上半年收购一家台湾经销商，并计划下半年于比利时及荷兰设立直销团队，进一步加强在亚太地区及欧洲、中东及非洲市场的影响力。- 集团善用全球商业化专长及庞大销售网络，与医疗器械同业建立战略合作，藉此丰富产品组合，并透过交叉销售创造额外收入。香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球医疗器械制造公司业聚医疗集团控股有限公司（"业聚医疗"或"集团"；股份代号：6929）今天宣布截至2025年6月30日止六个月("报告期")的中期业绩。尽管宏观经济环境未见明朗，集团的收入及纯利仍双双录得增长。美国市场增长强劲，加上亚太地区及欧洲、中东与非洲地区新兴市场的持续贡献，推动集团收入达到83.6百万美元，较去年同期上升5.9%。核心经营利润（自本公司拥有人应占利润撇除以股份为基础的薪酬开支、与税务亏损相关的递延税项资产的税务抵免净额及融资收入╱成本）为15.1百万美元，同比增长11.4%。公司拥有人应占利润同比上升5.1%至19.8百万美元。每股基本盈利为2.40美仙（2024年上半年：2.28美仙）。截至2025年6月30日，集团财务状况保持稳健，现金及银行结余达237.1百万美元。鉴于集团的财务状况稳健，以及为庆祝成立25周年，董事会议决宣派特别现金股息每股普通股15港仙，彰显集团致力为股东创造价值。连同截至2024年12月31日止年度之末期股息每股10港仙（已于2025年6月16日派付），股东于2025年合共获派股息每股25港仙。业聚医疗董事长、执行董事兼首席执行官钱永勋先生表示："过去25年，我们持续投资于创新及全球商业化能力，除了为业聚医疗建立了声誉，也助我们在不同的经济周期中破浪前行。尽管2025年上半年面临宏观经济及地缘政治的双重挑战，我们的全球布局仍展现韧性。美国市场增长印证了市场对我们的优质产品需求殷切，而我们亦透过庞大的销售网络，成功把握了亚太地区及欧洲、非洲及中东地区的增长机遇。我们将继续透过直销市场覆盖、卓越的销售支援、对创新的投入，以及全面的PCI和PTA产品组合提升品牌价值，从而强化竞争优势，为医生及患者提供更安全有效治疗方案的同时，也为股东创造长远回报。"全球销售网络及合作伙伴关系推动收入增长业聚医疗已建立覆盖逾70个国家及地区的销售网络，在13个地区设立直销团队并建立全球经销商网络，成为把握各地机遇、回应当地需求的重要一环。期内，受惠于印尼市场增长，以及Scoreflex TRIO 在新加坡及马来西亚获更广泛采用，亚太地区收入同比上升14.0%至27.3百万美元。欧洲、中东及非洲市场方面，德国、法国及西班牙等直销市场及包括英国、斯洛伐克及捷克共和国在内的分销市场的自有球囊类产品销售表现强劲，带动该区收入上升17.0%至22.4百万美元。尽管受关税因素影响，美国市场收入仍同比上升20.0%至8.0百万美元，主要受冠脉的普通及刻痕球囊，包括高价产品Scoreflex NC球囊，以及外周球囊销量显著上升所推动。而日本及中国境内市场的收入分别为16.1百万美元及9.7百万美元。凭借其广受认可的全球商业化能力，集团与立志走向国际巿场的同业合作，藉此丰富产品组合并开拓额外收入来源。继去年与深圳开立生物医疗科技股份有限公司成功展开合作，在香港及澳门分销血管内超声产品后，集团与该伙伴再度签订独家分销协议，在新加坡及马来西亚分销相关产品。至目前为止，合作范围已进一步扩展至集团旗下位于欧洲的4个直销市场，包括法国、德国、西班牙及瑞士，及其他6个分销市场。性能主导的多元化创新产品组合，提升市场差异化水平截至2025年6月30日，业聚医疗在全球主要司法管辖区拥有逾250项授权专利及已公布专利申请，及逾55款获批产品。期内，集团产品注册及临床试验继续取得进展，包括：- Sapphire 3的美国临床试验进展顺利，预期于2025年第四季度完成病人入组，以支持该产品的FDA纳入CTO适应症，从而与市场上其他传统半顺应性球囊形成差异化；- JADE PLUS及Teleport Glide获得CE标志、Teleport Glide及Scoreflex QUAD获得PMDA批准、COREPASS模组化微导管获得FDA批准、导引导管获得国家药监局批准；- 就Scoreflex TRIO、Sapphire ULTRA、Sapphire NC ULTRA、Sapphire NC 24、JADE PLUS、Teleport XT及Teleport Glide向国家药监局提交注册申请，并就Vascuaid抽吸导管及大管腔延长导管向PMDA提交注册申请。集团拥有庞大的产品管线。在冠状动脉领域，Sapphire PTX紫杉醇药物涂层球囊大约于2025年底在日本展开临床研究；外周方面，JADE Score球囊则预期于2026年向PMDA提交注册申请。合资企业业聚培福在中国境内展开的TricValve临床试验亦取得重大进展，参与医院数量上升，加快了病人入组进度。此外，业聚培福亦正透过"港澳注册药品及医疗器械进入大湾区计划"，积极推动大湾区各大医院采用TricValve。TricValve于2025年7月完成首次在中国境内进行的商业化植入手术，达到重要的里程碑。多区域生产基地缓解地缘政治风险截至2025年6月30日，业聚医疗于中国深圳、荷兰荷佛拉肯，以及德国莱茵河畔魏尔设有生产基地，总年产能约为210万件球囊及支架。自2023年底收购eucatech AG以来，集团已投入资源恢复其生产能力，期内产量逐步提升，以供应销售及临床注册所需产品。2025年8月，集团完成位于中国杭州、旗下最大研发及生产基地的主体结构建设，装修工程预期于下半年展开。该基地计划于2027年投产，届时将新增年产能240万件。钱先生总结说："有见于新兴市场的强劲势头、自研产品陆续成功推出巿场，以及已建立的战略合作，我们对2025年下半年前景保持乐观。除了亚太地区及欧洲、中东及非洲将继续担当主要的增长引擎，我们亦计划将部分市场由分销模式转为直销模式，以强化当地营收能力及市场渗透。欧洲市场将透过于比利时及荷兰设立直销团队加强市场影响力；日本市场则藉新产品上市重拾增长动力；而在中国境内市场，我们则把握政策支持，扩大产品覆盖并加速商业化进程。随着关税争端缓和，美国市场的产品交付亦有望加快。凭借业聚医疗多元化的产品组合、稳健的财务状况及规模经济效益，我们具备优势构建具韧性及竞争力的业务体系，为持份者创造可持续的价值。"关于业聚医疗集团控股有限公司业聚医疗是一家全球医疗器械制造公司，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。本集团总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至结构性心脏病领域。凭借拥有逾20年产品开发经验的内部研发团队，本集团已开发出世界领先的专有技术。如需了解更多详情，请访问集团官网：https://orbusneich.com/ Copyright 2025 亚太商讯 via SeaPRwire.com.

广州，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 近日，中国电子信息行业联合会公布最新一批获颁数据管理能力成熟度（简称"DCMM"）等级证书企业名单，广发证券获评最高等级五级（优化级）认证，成为行业首家获评最高等级的证券公司，标志着公司在数据管理和应用方面达到国内领先水平，为行业数据管理能力建设树立标杆。《数据管理能力成熟度评估模型》（GB/T 36073-2018）是我国数据管理领域正式发布的首个国家标准。该认证从数据战略、数据治理、数据架构、数据应用等多个维度，全面评估企业的数据管理能力。其中，五级（优化级）作为最高等级，标志着企业的数据管理已形成行业最佳实践，具备强大的示范引领作用。一直以来，广发证券高度重视数据管理能力的建设与提升，将数据视为企业核心资产。公司构建了"战略引领、全员参与、跨部门协同、全生命周期管理"的数据管理体系。通过制定清晰的数据战略规划，完善数据治理组织架构与制度流程，强化数据安全与合规管理，持续提升数据质量与应用效能，公司实现了数据管理从"规范"到"优化"的跨越式发展，为业务创新、客户服务升级及风险管理提供了强有力的数据支撑。广发证券副总经理、首席信息官辛治运表示："公司将以此次获得DCMM五级认证为新的起点，持续深化数据管理能力建设，进一步完善数据治理长效机制，推动数据技术与业务场景的深度融合，并以此为契机，不断提升服务实体经济的质效，为证券行业的数据管理创新与发展贡献更多力量。" Copyright 2025 亚太商讯 via SeaPRwire.com.